Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.63 |
| ▸ | EDNRB | P24530 | 8/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241068 | 0.89 | EDNRA (0.61) | EDNRAEDNRBNPSR1RXFP1MEN1 | |
| SCHEMBL7716850 | 0.79 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL2239357 | 0.78 | ALDH1A1 (0.74) | MEN1CYP2C9CYP2C19KMT2AKDM4E | |
| SCHEMBL6152009 | 0.76 | EDNRA (1.00) | EDNRAEDNRBNPSR1RXFP1MEN1 | |
| SCHEMBL2555583 | 0.76 | EDNRA (0.67) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7856718 | 0.74 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7850007 | 0.74 | EDNRA (0.81) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL7850038 | 0.74 | EDNRA (0.74) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL17352253 | 0.74 | CCNT1 (0.71) | EDNRAEDNRBNPSR1RXFP1CCNT1 | |
| Sulfisoxazole SCHEMBL23467 | 0.73 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | EDNRA 1443/4885EDNRB 1645/4885NPSR1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.